123 related articles for article (PubMed ID: 27023610)
21. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
23. Ubiquitin E3 ligase SCF(β-TRCP) regulates TRIB2 stability in liver cancer cells.
Qiao Y; Zhang Y; Wang J
Biochem Biophys Res Commun; 2013 Nov; 441(3):555-9. PubMed ID: 24211582
[TBL] [Abstract][Full Text] [Related]
24. Phosphomimetic mutation of the N-terminal lid of MDM2 enhances the polyubiquitination of p53 through stimulation of E2-ubiquitin thioester hydrolysis.
Fraser JA; Worrall EG; Lin Y; Landre V; Pettersson S; Blackburn E; Walkinshaw M; Muller P; Vojtesek B; Ball K; Hupp TR
J Mol Biol; 2015 Apr; 427(8):1728-47. PubMed ID: 25543083
[TBL] [Abstract][Full Text] [Related]
25. The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma.
Geli J; Kiss N; Lanner F; Foukakis T; Natalishvili N; Larsson O; Kogner P; Höög A; Clark GJ; Ekström TJ; Bäckdahl M; Farnebo F; Larsson C
Endocr Relat Cancer; 2007 Mar; 14(1):125-34. PubMed ID: 17395981
[TBL] [Abstract][Full Text] [Related]
26. Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions.
Ma J; Xue Y; Cui W; Li Y; Zhao Q; Ye W; Zheng J; Cheng Y; Ma Y; Li S; Han T; Miao L; Yao L; Zhang J; Liu W
Cancer; 2012 Sep; 118(17):4105-16. PubMed ID: 22907703
[TBL] [Abstract][Full Text] [Related]
27. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma.
Chow LS; Lo KW; Kwong J; Wong AY; Huang DP
Oncol Rep; 2004 Oct; 12(4):781-7. PubMed ID: 15375500
[TBL] [Abstract][Full Text] [Related]
28. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
[TBL] [Abstract][Full Text] [Related]
29. Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2.
Pettersson S; Kelleher M; Pion E; Wallace M; Ball KL
Biochem J; 2009 Mar; 418(3):575-85. PubMed ID: 19032150
[TBL] [Abstract][Full Text] [Related]
30. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer.
Irimia M; Fraga MF; Sanchez-Cespedes M; Esteller M
Oncogene; 2004 Nov; 23(53):8695-9. PubMed ID: 15378027
[TBL] [Abstract][Full Text] [Related]
31. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
32. The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.
Simerzin A; Zorde-Khvalevsky E; Rivkin M; Adar R; Zucman-Rossi J; Couchy G; Roskams T; Govaere O; Oren M; Giladi H; Galun E
Hepatology; 2016 Nov; 64(5):1623-1636. PubMed ID: 27302319
[TBL] [Abstract][Full Text] [Related]
33. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
Brignone C; Bradley KE; Kisselev AF; Grossman SR
Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
[TBL] [Abstract][Full Text] [Related]
34. Mdm2 as a chromatin modifier.
Wienken M; Moll UM; Dobbelstein M
J Mol Cell Biol; 2017 Feb; 9(1):74-80. PubMed ID: 27927750
[TBL] [Abstract][Full Text] [Related]
35. The SCFβ-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis.
Shimizu K; Fukushima H; Ogura K; Lien EC; Nihira NT; Zhang J; North BJ; Guo A; Nagashima K; Nakagawa T; Hoshikawa S; Watahiki A; Okabe K; Yamada A; Toker A; Asara JM; Fukumoto S; Nakayama KI; Nakayama K; Inuzuka H; Wei W
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049764
[TBL] [Abstract][Full Text] [Related]
36. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
37. Interaction of the growth and tumour suppressor NORE1A with microtubules is not required for its growth-suppressive function.
Moshnikova A; Kuznetsov S; Khokhlatchev AV
BMC Res Notes; 2008 May; 1():13. PubMed ID: 18710533
[TBL] [Abstract][Full Text] [Related]
38. Nore1a drives Ras to flick the P53 senescence switch.
Donninger H; Clark GJ
Mol Cell Oncol; 2016 May; 3(3):e1055050. PubMed ID: 27314075
[TBL] [Abstract][Full Text] [Related]
39. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases.
Aoyama Y; Avruch J; Zhang XF
Oncogene; 2004 Apr; 23(19):3426-33. PubMed ID: 15007383
[TBL] [Abstract][Full Text] [Related]
40. Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review.
Shaikh MF; Morano WF; Lee J; Gleeson E; Babcock BD; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2016 Dec; 46(6):627-634. PubMed ID: 27993876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
